Bristol Has Appetite For Obesity: Firm To License Solvay Phase I Cannabinoid Antagonist
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies will jointly develop and commercialize SLV319. Potential inroad into obesity market aligns with Bristol's long-term focus on "high-potential disease areas," company says.